Form 4: Astrana Health Director Linda Marsh Receives Restricted Stock Grant

Astrana Health, Inc. Director Linda Marsh was granted 6,449 shares of common stock as restricted stock, vesting by June 2026 or the 2026 annual meeting.

Summary

• Linda Marsh, a Director of Astrana Health, Inc. (ASTH), acquired 6,449 shares of common stock.
• The transaction occurred on June 11, 2025, and was reported on June 13, 2025.
• The shares were acquired as a grant of restricted stock with a price of $0 per share.
• These restricted shares are part of the Issuer's 2024 Equity Incentive Plan.
• The shares will vest on the earlier of June 11, 2026, or the date of Astrana Health's 2026 annual meeting of stockholders.
• Following this transaction, Linda Marsh beneficially owns 83,641 shares of Astrana Health common stock, which includes the newly granted 6,449 restricted shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects a standard practice of aligning director interests with shareholders through equity compensation, which is generally viewed favorably. It is a routine transaction and not indicative of significant operational changes.

Positives

• The grant of restricted stock to a director aligns their financial interests with those of the company's shareholders, encouraging long-term value creation.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent equity compensation strategy.

Future Outlook

The 6,449 restricted shares granted to Director Linda Marsh are scheduled to vest on the earlier of June 11, 2026, or the date of Astrana Health's 2026 annual meeting of stockholders, indicating a future equity inflow for the director.

Industry Context

The grant of restricted stock to a director is a common and standard practice in the U.S. corporate landscape for executive and director compensation, aiming to align the interests of leadership with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock as part of director compensation is a widely adopted practice across various industries, including healthcare services, to incentivize long-term commitment and performance.
• Companies like UnitedHealth Group (UNH), CVS Health (CVS), and Elevance Health (ELV) frequently utilize similar equity-based compensation plans for their non-employee directors, often tied to vesting schedules over one to three years or until the next annual meeting.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of common stock to Linda Marsh, a Director of Astrana Health, Inc., which is a related party transaction as part of her compensation.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director helps align the director's long-term interests with those of the shareholders, potentially leading to better governance and strategic decisions aimed at increasing shareholder value.
• Employees: No direct impact mentioned, but such compensation practices can set precedents for broader employee equity programs.

Next Steps

• The 6,449 restricted shares will vest on the earlier of June 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Astrana Health, ASTH, SEC Form 4, Insider Transaction, Restricted Stock, Equity Grant, Director Compensation, Linda Marsh, Corporate Governance